Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16755143 | 1.00 | KMT2A (0.58) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL23611929 | 1.00 | KMT2A (0.58) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL16755142 | 1.00 | KMT2A (0.58) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL16732777 | 1.00 | KMT2A (0.58) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL25281173 | 0.90 | CA1 (0.47) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL24439605 | 0.90 | CA1 (0.47) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL23624647 | 0.86 | KMT2A (0.44) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL23611982 | 0.86 | KMT2A (0.44) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL23624897 | 0.86 | KMT2A (0.44) | KMT2ABTKCA1CA2CA7 | |
| SCHEMBL23625138 | 0.86 | KMT2A (0.44) | KMT2ABTKCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473284-B2 | Small molecule inhibitors of ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-18 | — | — | US | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| WO-2021138331-A2 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138331-A2 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-08 | — | — | WO | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-1299362-A4 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1299362-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002006245-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMARCEUTICAL CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | ULK1, ULK2, ULK3 | KMT2A 2653/4885BTK 1090/4885CA1 4704/4885 |
| US-12473284-B2 | Small molecule inhibitors of ULK1 | ULK1, ULK2, ULK3 | KMT2A 2653/4885BTK 1090/4885CA1 4704/4885 |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | KMT2A 484/4885BTK 305/4885CA1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.